Evidence map›Paper›PMID 36443758›Full record

ArticleAnnals of clinical microbiology and antimicrobials2022

Third-generation cephalosporin resistant gram-negative bacteraemia in patients with haematological malignancy; an 11-year multi-centre retrospective study.

Jara R de la Court, Sjoukje H S Woudt, Annelot F Schoffelen, Jarom Heijmans, Nick A de Jonge, Tjomme van der Bruggen, Marije K Bomers, Merel M C Lambregts, Rogier P Schade, Kim C E Sigaloff and 1 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Annals of clinical microbiology and antimicrobials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Jara R de la Court *Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. j.delacourt@amsterdamumc.nl.
Sjoukje H S Woudt *Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
Annelot F SchoffelenCentre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
Jarom HeijmansDepartment of Haematology, Amsterdam UMC, University of Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Nick A de JongeDepartment of Haematology, Amsterdam UMC, University of Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Tjomme van der BruggenDepartment of Medical Microbiology, University Medical Centre Utrecht, University Utrecht, Utrecht, The Netherlands.
Marije K BomersDivision of Infectious Diseases, Department of Internal Medicine, Amsterdam UMC, University of Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Merel M C LambregtsDepartment of Infectious Diseases, Leiden University Medical Centre, Leiden University, Leiden, The Netherlands.
Rogier P SchadeDepartment of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Kim C E SigaloffDivision of Infectious Diseases, Department of Internal Medicine, Amsterdam UMC, University of Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
ISIS-AR study group
Amsterdam University Medical Centers · NLUtrecht University · NLLeiden University · NLNational Institute for Public Health and the Environment · NLAmsterdam Neuroscience · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesAmong patients with haematological malignancy, bacteraemia is a common complication during chemotherapy-induced neutropenia. Resistance of gram-negative bacteria (GNB) to third-generation cephalosporins (3GC) is increasing. In order to explore the value of using surveillance cultures to guide empirical treatment e.g. choosing between carbapenem versus ceftazidime- we aimed to assess the distribution of pathogens causing bacteraemia in patients with haematological malignancy, and the proportion of 3GC-resistant GNB (3GC-R GNB) bacteraemia that was preceded by 3GC-R GNB colonization.

methodsUsing 11 years of data (2008-2018) from the Dutch national antimicrobial resistance surveillance system, we assessed the prevalence of 3GC-R GNB in episodes of bacteraemia, and the proportion of 3GC-R GNB bacteraemia that was preceded by 3GC-R GNB colonization. Colonization was defined as availability of any GNB surveillance isolate in the year before, independent of the causative micro-organism (time-paired isolates).

resultsWe included 3887 patients, representing 4142 episodes of bacteraemia. GNB were identified in 715/4142 (17.3%), of which 221 (30.9%) were 3GC-R GNB. In 139 of these 221 patients a time-paired surveillance culture was available. In 76.2% (106/139) of patients these surveillance cultures already showed 3GC-R GNB isolates in the year prior to the culture date of the 3GC-R GNB positive blood isolate.

conclusionsThis multi-centre study shows that in patients with haematological malignancy, the majority of 3GC-R GNB bacteraemia is preceded by 3GC-R GNB colonization. Prospective clinical studies are needed to assess the safety and benefits of the use of surveillance-cultures to guide empirical therapy to restrict the empirical use of carbapenems in this population.

Indexed as

BacteremiaHematologic NeoplasmsCarbapenemsCeftazidimeHumansProspective StudiesRetrospective StudiesCarbapenemsCeftazidimeAntimicrobial resistanceColonization.Empirical antibiotic therapyFebrile neutropeniaResistance surveillanceThird-generation-cephalosporin resistance

Identifiers

PMID36443758
PMCPMC9707019
OpenAlexW4310157670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.